Skip to Content
Merck
CN

553015

Sigma-Aldrich

Raf Kinase Inhibitor V - CAS 918505-84-7 - Calbiochem

The Raf Kinase Inhibitor V, also referenced under CAS 918505-84-7, controls the biological activity of Raf Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Synonym(s):

Raf Kinase Inhibitor V - CAS 918505-84-7 - Calbiochem, Propane-1-sulfonic acid-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl)-amide, PLX4720

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C17H14ClF2N3O3S
CAS Number:
Molecular Weight:
413.83
UNSPSC Code:
12352200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥95% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

orange-yellow

solubility

DMSO: 100 mg/mL
ethanol: 5 mg/mL

shipped in

ambient

storage temp.

2-8°C

General description

A cell-permeable azaindole compound that interacts with Raf via both the ATP-binding site and a "Raf-selective pocket" that exhibits conformation-dependent inhibitor-binding modes and accounts for the compound′s preferential binding and inhibitory activity toward the active Raf mutants (IC50 = 6.7, 13, 130, 160, and >1,300 nM against C-Raf-1Y340D/Y341D, B-RafV600E, BRK, WT B-Raf, and 64 other kinases, respectively). Shown to inhibit the proliferation and cellular Erk phosphorylation much more potently in B-RafV600E-bearing than WT B-Raf-bearing cancer cell lines in vitro and effectively suppress COLO205-derived tumor growth in mice in vivo (near complete regression during the 1-wk treatment period; 20 mg/kg, daily p.o.).
A cell-permeable azaindole compound that interacts with Raf via both the ATP-binding site and a "Raf-selective pocket" that exhibits conformation-dependent inhibitor-binding modes and accounts for the compound′s preferential binding and inhibitory activity toward the active Raf mutants (IC50 = 6.7, 13, 130, 160, and >1,300 nM against C-Raf-1Y340D/Y341D, B-RafV600E, BRK, WT B-Raf, and 64 other kinases, respectively). Shown to inhibit the proliferation and cellular Erk phosphorylation much more potently in B-RafV600E-bearing than WT B-Raf-bearing cancer cell lines in vitro and effectively suppress COLO205-derived tumor growth in mice in vivo (near complete regression during the 1-wk treatment period; 20 mg/kg, daily, p.o.).

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Tsai, J., et al. 2008. Proc. Natl. Acad. Sci. USA105, 3041.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Gang Cheng et al.
Cancer treatment and research communications, 25, 100210-100210 (2020-09-29)
Melanoma is an aggressive form of skin cancer for which there are no effective drugs for prolonged treatment. The existing kinase inhibitor antiglycolytic drugs (B-Raf serine/threonine kinase or BRAF inhibitors) are effective for a short time followed by a rapid

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service